Abvc biopharma subsidiary biokey projects $1.0 million proceeds from dietary supplement production

Fremont, ca, june 20, 2023 (globe newswire) -- via newmediawire -- abvc biopharma, inc. (nasdaq: abvc), a clinical-stage biopharmaceutical company specializing in therapeutic solutions in oncology/hematology, cns, and ophthalmology, announced today that its wholly owned subsidiary, biokey, inc., is in the second year of a 3-year agreement to manufacture dietary supplements derived from the maitake mushroom in tablet and liquid forms.
ABVC Ratings Summary
ABVC Quant Ranking